Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.51 |
| ▸ | FPR1 | P21462 | 1/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19512864 | 0.88 | TSHR (0.63) | TSHRL3MBTL1KMT2AKDM4ELMNA | |
| SCHEMBL27315337 | 0.87 | L3MBTL1 (0.69) | TSHRL3MBTL1KMT2AKDM4ELMNA | |
| SCHEMBL2038892 | 0.81 | KMT2A (0.58) | TSHRL3MBTL1KMT2ALMNAIDO1 | |
| SCHEMBL8330091 | 0.81 | TSHR (0.59) | TSHRL3MBTL1KMT2AKDM4ELMNA | |
| SCHEMBL6304376 | 0.81 | TSHR (0.59) | TSHRL3MBTL1KMT2AKDM4ELMNA | |
| SCHEMBL2455662 | 0.81 | TSHR (0.55) | TSHRL3MBTL1KMT2AKDM4ELMNA | |
| SCHEMBL9130527 | 0.81 | AAK1 (0.59) | TSHRL3MBTL1KMT2AALDH1A1MAPT | |
| SCHEMBL9130537 | 0.81 | AAK1 (0.59) | TSHRL3MBTL1KMT2AALDH1A1MAPT | |
| SCHEMBL2509706 | 0.80 | ALPL (0.58) | TSHRL3MBTL1IDO1ALDH1A1CYP1A2 | |
| SCHEMBL21637690 | 0.80 | TSHR (0.61) | TSHRL3MBTL1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0000892-B1 | ORGANOPOLYSILOXANE COMPOSITIONS WITH MICROBICIDAL ACTIVITY THAT CAN BE STORED IN THE ABSENCE OF WATER | BAYER AG (DE) | 1981-03-18 | — | — | EP | claimed |
| US-4228065-A | Microbiocidal organopolysiloxane molding compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-14 | — | — | US | claimed |
| EP-0000892-A1 | Organopolysiloxane compositions with microbicidal activity that can be stored in the absence of water | BAYER AG (DE) | 1979-03-07 | — | — | EP | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| EP-0000892-B1 | ORGANOPOLYSILOXANE COMPOSITIONS WITH MICROBICIDAL ACTIVITY THAT CAN BE STORED IN THE ABSENCE OF WATER | BAYER AG (DE) | 1981-03-18 | — | — | EP | disclosed |
| US-4228065-A | Microbiocidal organopolysiloxane molding compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-14 | — | — | US | disclosed |
| US-4228065-A | Microbiocidal organopolysiloxane molding compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-14 | — | — | US | disclosed |
| EP-0000892-A1 | Organopolysiloxane compositions with microbicidal activity that can be stored in the absence of water | BAYER AG (DE) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | TSHR 2000/4885L3MBTL1 4239/4885KMT2A 3722/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | TSHR 4379/4885L3MBTL1 4171/4885KMT2A 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.